Nurse staffing levels keeping re-hospitalizations down for hip and knee patients
A new study from the University of Pennsylvania School of Nursing
A new study from the University of Pennsylvania School of Nursing
An interactive web system with the help of your mobile phone can be an effective tool for better blood pressure control. Test persons lowered their blood pressure, were better able to understand how their lifestyle affects their blood pressure and actively participated in follow-up discussions.
Well controlled blood pressure reduces the risk for cardio-vascular complications. In addition to taking daily medication, persons with high blood pressure need to understand the sometime complicated connection between the blood pressure values and daily life. Blood pressure medication combined with changes in lifestyle gives good results, but despite awareness of this, few people are able to reach a well controlled blood pressure.
In her thesis, researcher Ulrika Bengtsson developed and evaluated an interactive system for persons living with high blood pressure that, with the help of their own mobile phone, can be used to self-manage the high blood pressure on a daily basis.
Depression is a known risk factor for cardiovascular disease, but as a person
A new breast cancer survivorship care guideline created by the American Cancer Society and the American Society of Clinical Oncology provides guidance to primary care and other clinicians in caring for the estimated 3.1 million female adult survivors of breast cancer in the United States. The guideline is the third in a continuing series of guidelines to provide guidance on identifying and managing potential physical and psychosocial long-term and late effects of cancer and its treatment, as well as other key elements of adult post-treatment survivorship care. Previous guidelines address the needs of survivors of prostate and colorectal cancers.
The guideline recommends that breast cancer patients should undergo regular surveillance for breast cancer recurrence, including evaluation with a detailed cancer-related history and physical examination, and should be screened for new primary breast cancer consistent with guidelines. At the same time, data do not support performing routine laboratory tests or imaging tests, except mammography when indicated, in asymptomatic patients to evaluate for breast cancer recurrence.
The guideline also recommends that primary care clinicians counsel patients about the importance of maintaining a healthy lifestyle, monitor for post-treatment symptoms that can adversely affect quality of life, and counsel patients to adhere to endocrine therapy. In addition to recommendations about screening tests and lifestyle factors, the guideline includes information on a broad range of other issues, from cognitive impairment and body image to fatigue and care coordination.
Scientists from the Department of Chemistry, in collaboration with the Healing Foundation Children
Scientists from the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) have set out to help build the world’s first total-body positron emission tomography (PET) scanner, a medical imaging device that could change the way cancers and other diseases are diagnosed and treated.
The project is a consortium led by a UC Davis research team and includes scientists from Berkeley Lab and the University of Pennsylvania. It’s supported by a recently announced five-year, $15.5 million ( Euro 13 million) Transformative Research Award from the National Institutes of Health.
The consortium’s goal is to build a PET scanner that images the entire human body simultaneously, a big jump from today’s PET scanners that only scan 20-cm segments at a time. In addition to being able to diagnose and track the trajectory of a disease in a way not possible today, a total-body PET scanner would reduce a patient’s radiation dose by a factor of 40, or decrease scanning time from 20 minutes to just 30 seconds.
Berkeley Lab’s contribution, led by William Moses of the Molecular Biophysics and Integrated Bioimaging Division, is to develop electronics that send data collected by the scanner’s detectors to a computer, which converts the data into a three-dimensional image of the patient. The new scanner will have half a million detectors, and the data from each detector must be electronically transmitted to a computer, so the task is incredibly complex.
‘We’re developing the electronic interface between the detectors and the computer algorithm-and the electronics for this scanner is an order of magnitude more complicated than what’s been done before,’ says Moses. ‘But Berkeley Lab has a long history developing instrumentation for nuclear medical imaging, including PET scanners, and this project is another milestone in our research.’
The total-body PET scanner is the latest project in Berkeley Lab’s PET-related research, coming at a time when technology has advanced to the point that it s possible to efficiently process the data generated from the scanner’s half a million detectors.
Lawrence Berkeley National Laboratoryhttp://tinyurl.com/zyqhukj
The lab of Patrick Aebischer at EPFL has developed a bioactive capsule containing cells that have been genetically engineered to produce antibodies against Abeta. The capsule is implanted in the tissue under the skin, and over time the cells produce and release a steady flow of antibodies into the bloodstream, from where they cross over into the brain to target the Abeta plaques.
Before going into capsule, the cells are first genetically engineered to produce antibodies that specifically recognize and target Abeta. The cells of choice are taken from muscle tissue, and the permeable membranes let them interact with the surrounding tissue to get all the nutrients and molecules they need.
A new study conducted at Columbia University Medical Center (CUMC) has revealed some of the underlying mechanisms that may increase the risk of heart disease in people with sleep apnoea. The study also found that statins
A recent study found that cervical cancer patients without enlarged lymph nodes could benefit from SPECT-MRI imaging of their sentinel lymph nodes (SLNs) to assess whether metastases are present.
Cervical cancer is the fourth most common cancer in women worldwide, with more than 500,000 new cases globally each year. According to a 2014 University of Maryland study, cervical cancer affects 18.6 women per 100,000 in the United States. Early diagnosis is critical. Although surgical removal and examination of the sentinel lymph nodes remains the most accurate way to determine whether the cancer has spread to the lymph nodes, SPECT-MRI imaging may reduce false negative MRI findings in early-stage patients and potentially save some from invasive diagnostic procedures.
Researchers at the University Medical Center Utrecht, Netherlands, used Tc-99m-nanocolloid SPECT-MRI fusion for the assessment of SLNs (for size and absence of sharp demarcation) in patients with early-stage cervical cancer.
Jacob P. Hoogendam, MD, the corresponding author of the study, notes,
At conhIT – Connecting Healthcare IT, Europe’s leading event for the Health IT industry which takes place from 19 to 21 April in Berlin – a competition will be presenting an award for the best health app once again.
This event, part of the internationally recognized AppCircus series, will be taking place for the second time, and is regarded as the world’s biggest competition for mHealth apps. Taking part gives companies and mHealth app developers an opportunity to present their products to an outstanding audience and to increase awareness of their companies in the Health IT sector. At conhIT 2016 more than 7,500 visitors and some 400 exhibitors are expected to attend.
The competition will be looking for an app that assists the daily work of medical professionals, nurses and patients and can be used in Europe in hospitals, rehab centres, care homes and general patient care.
The award ceremony will take place on 20 April 2016 in the mobile health zone at conhIT. This section of the exhibition focuses on innovations and trends in mobile health applications.
The winner of the conhIT AppCircus competition will be nominated for the Mobile Premier Awards, the world’s biggest app exhibition at the Mobile World Congress in Barcelona.
www.conhit.com
April 2024
The medical devices information portal connecting healthcare professionals to global vendors
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlyCookie settingsWe may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Privacy policy